Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃
As the importance of natural products in drug development becomes increasingly prominent, flavonoids have become a hot topic in natural medicine research due to their diverse bioactivity and lower toxicity side effects. Hibifolin, a flavonol glycoside derived from Helicteres isora, has attracted widespread attention in recent years due to its unique pharmacological activity. This compound not only exhibits significant neuroprotective effects but also possesses antibacterial activity, particularly showing potential clinical value in inhibiting the pathogenic mechanism of Staphylococcus aureus. This paper aims to systematically review the chemical structure, plant origin, pharmacological activity, mechanism of action, and druggability evaluation of cottoncetin-8-O-glucuronidan, exploring its future application prospects in neurodegenerative and infectious diseases.
Cottonskin-8-O-glucuronic acid (CAS No.: 55366-56-8) is a flavonol glycoside with a molecular weight of 494.3610 and a molecular formula of C_23H_22O_13. Its structural feature is that the flavonoid backbone of the hibifolin core forms glycosidic bonds with glucuronic acid via the 8-position hydroxyl group. This structure imparts high polarity, showing a low LogP value (-0.1733), indicating strong hydrophilicity, water solubility of 1.3225, and TPSA (topological pole surface area) as high as 247.81 Ų, indicating a rich polar group that affects its cell membrane penetration ability.
In terms of physicochemical properties, cottoncetin-8-O-glucuronide exhibits low blood-brain barrier permeability, suggesting that its direct role in the central nervous system may be limited, but it still holds potential value by modulating peripheral neuroprotective mechanisms or indirect pathways. It does not show hERG channel inhibition, and the Ames test result is 0.6, indicating low genotoxicity risk and good safety.
Cottoncetin-8-O-glucuronide is mainly isolated from Helicteres isora. H. isora is a plant in the genus H. isora in the Malvaceae family, widely distributed in tropical and subtropical Asia, traditionally used to treat inflammation, digestive system diseases, and infections.
The extraction process typically uses ethanol or methanol as solvents for crude extraction, followed by liquid-liquid separation and column chromatography techniques (such as silica gel columns, reversed-phase C18 columns) for separation and purification. High-performance liquid chromatography (HPLC) and mass spectrometry (LC-MS) are used for component identification and purity testing. In recent years, the application of ultrasound-assisted extraction and microwave-assisted extraction technologies has improved extraction efficiency and yield, providing technical support for large-scale preparation.
Cottoncetin-8-O-glucuronic acid shows significant protective effects in neurodegenerative disease models. β-amyloid (Aβ) aggregation is a key pathological hallmark of Alzheimer's disease (AD), and Aβ-induced neurotoxicity is closely related to apoptosis. Research shows that cottoncetin-8-O-glucuronic acid can effectively inhibit Aβ-induced neuronal cell death, significantly reduce the activation levels of caspase-3 and caspase-7, and slow down the apoptosis process. Additionally, this compound can induce phosphorylation of the Akt signaling pathway in cortical neurons, promoting the activation of cell survival signals and thereby enhancing neurons' resilience.
Cottoncetin-8-O-glucuronide acts as a natural Sortase A (SrtA) inhibitor, with an IC50 value of 31.2 μM. SrtA is a key enzyme for protein anchoring on the surface of Gram-positive bacteria, involved in bacterial adhesion, invasion, and biofilm formation. By directly binding to the SrtA protein, cottoncetin-8-O-glucuronide effectively inhibits the pathogenic behavior of Staphylococcus aureus, reducing its biofilm-forming ability and thereby lowering bacterial infectivity and drug resistance.
In animal experiments, this compound significantly improved the survival rate of pneumonia induced by Staphylococcus aureus in mouse models and reduced pathological lung tissue damage. Additionally, the combination of cottoncetin-8-O-glucuronide and cefotaxime demonstrated synergistic antibacterial effects, suggesting its potential value in combined antibacterial therapy.
Flavonoids generally have antioxidant activity, and cotton cetin-8-O-glucuronic acid is no exception. It works by regulating various antioxidant-related targets, including tyrosinase (TYR), matrix metalloproteinase 1 (MMP1), nuclear factor red blood cell 2-related factor 2 (NFE2L2/NRF2), superoxide dismutase (SOD1, SOD2), catalase (CAT), glutathione peroxidase 1 (GPX1), heme oxygenase 1 (HMOX1), and matrix metalloproteinase 3 (MMP3). By activating the NRF2 signaling pathway, cottoncetin-8-O-glucuronic acid enhances the expression of intracellular antioxidant enzymes, reduces oxidative stress damage, and protects cellular function.
Adenosine deaminase (ADA) is an important enzyme involved in purine metabolism, regulating immune responses and cellular signal transduction. Cottonskin-8-O-glucuronide as an ADA inhibitor with a Ki value of 49.92 μM competitively inhibits ADA activity, regulates intracellular adenosine levels, indirectly affects immune cell function and inflammatory responses, and helps alleviate neuroinflammation and immune-mediated disease progression.
Cottoncetin-8-O-glucuronide binds directly to the SrtA protein, inhibiting its enzymatic activity, blocking the anchoring process of bacterial surface proteins, and weakening bacterial adhesion and biofilm formation. This mechanism not only weakens bacterial pathogenicity but also reduces antibiotic resistance, enhancing the effectiveness of antimicrobial treatment.
Cottoncetin-8-O-glucuronide induces Akt phosphorylation, activates the PI3K/Akt signaling pathway, and promotes cell survival and anti-apoptotic responses. This signaling pathway plays a central role in neuronal protection, inhibiting the activation of caspase-3 and caspase-7, thereby reducing apoptosis. Additionally, by regulating NRF2-mediated antioxidant reactions, oxidative stress reduces neuronal damage and synergistically exerts neuroprotective effects.
The molecular weight of cottoncetin-8-O-glucuronide was 494.3610, close to the upper limit of the Lipinski rule, and the LogP value was -0.1733, indicating strong hydrophilicity and possibly affecting oral bioavailability. A high TPSA (247.81 Ų) suggests its high polarity, which may limit cell membrane permeability and blood-brain barrier penetration, consistent with experimental data indicating low blood-brain barrier penetration.
In terms of safety, this compound does not inhibit hERG channels, reducing the risk of cardiotoxicity; The Ames test result was 0.6, indicating a low risk of genotoxicity. Moderate water solubility, which is beneficial for drug formulation development.
Currently, systematic studies on its pharmacokinetics are limited, and further evaluation of its in vivo absorption, distribution, metabolism, and excretion characteristics (ADME) is needed in the future, especially for optimizing administration strategies for central nervous system diseases. In addition, considering its synergistic antibacterial effect with cefotaxime, the pharmacokinetic interactions of combination therapy also require in-depth study.
Cottoncetin-8-O-glucuronide shows broad application potential in neurodegenerative diseases and bacterial infections. Its protective effect against Aβ-induced neurotoxicity and inhibition of key apoptotic enzymes suggest its potential value in adjunctive therapy for neurodegenerative diseases such as Alzheimer's disease. Although its blood-brain barrier penetration is relatively low, drug carrier technology or structural modification is expected to enhance the bioavailability of the central nervous system.
In terms of antibacterial activity, cottoncetin-8-O-glucuronide acts as an SrtA inhibitor, providing a novel anti-infective strategy targeting the pathogenic mechanism of Staphylococcus aureus. Its synergistic effect with traditional antibiotics opens new avenues for addressing antibiotic resistance issues. In the future, further preclinical and clinical trials can be conducted to verify its safety and efficacy.
Additionally, the antioxidant activity of cottoncetin-8-O-glucuronide gives it potential for use in various oxidative stress-related diseases, such as cardiovascular diseases, diabetes, and inflammatory diseases. By combining modern drug design with nanotechnology, it is expected to realize the advantages of multi-target synergistic therapy.
Cottonskin-8-O-glucuronic acid glycosides, a natural flavonoid glycoside derived from Isomosaic mushrooms, have become an important subject for natural drug research due to their unique chemical structure and diverse biological activities. Its significant effects in neuroprotection, antibacterial, and antioxidant effects reveal its potential as a candidate molecule for novel drugs. In the future, by deeply analyzing its mechanism of action, optimizing pharmacokinetic properties, and conducting systematic clinical evaluations, cottoncetin-8-O-glucuronide is expected to become an effective drug for treating neurodegenerative diseases and bacterial infections, providing new ideas and strategies for related treatments.
